pheochromocytoma
PHEOCHROMOCYTOMA
Pheochromocytoma is a rare adrenal gland tumor that may precipitate life-threatening hypertension.
It can occur at any age but usually occurs during young to mid-adult life.
Majority of patients presents with ≥1 of the following hypertension resistant to standard antihypertensive treatment, hypertensive crisis with malignant hypertension, hypertensive encephalopathy, aortic dissection, or myocardial infarction and paroxysmal symptoms which suggest seizure disorder, anxiety attacks or hyperventilation.
  1. Bentrem DJ, Pappas SG, Ahuja Y, et al. Contemporary surgical management of pheochromocytoma. Am J Surg. 2002 Dec;184(6):621-625. PMID: 12488192
  2. Janetschek G, Neumann HP. Laparoscopic surgery for pheochromocytoma. Urol Clin North Am. 2001 Feb;28(1):97-105. PMID: 11277073
  3. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab. 2004 Feb;89(2):479-491. PMID: 14764749
  4. Klingler HC, Klingler PJ, Martin K, et al. Pheochromocytoma. Urology. 2001 Jun;57(6):1025-1032. PMID: 11377298
  5. Nguyen-Martin M, Hammer GD. Pheochromocytoma: an update on risk groups, diagnosis, and management. Hospital Physician. 2006 Feb:17-24
  6. Vierhapper H. Adrenocortical tumors: clinical symptoms and biochemical diagnosis. Eur J Radiol. 2002 Feb;41(2):88-94. PMID: 11809538
  7. Pheochromocytoma. Harrison's Online: McGraw-Hill Companies; 2003. http://harrisonsonline.com
  8. MedWormhttp://www.medworm.com/rss/index.php/Endocrinology/15/http://www.medworm.com/rss/medicalfeeds/specialities/Endocrinology.xml
  9. MedWormhttp://www.medworm.com/rss/index.php/Cancer-%26-Oncology/6/http://www.medworm.com/rss/medicalfeeds/specialities/Cancer-Oncology.xml
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 17 Oct 2017

Patients with type 2 diabetes (T2D) may not necessarily have lower trabecular bone scores (TBS) than nondiabetics, a finding that contrasts with that of previous research, according to a study published in a poster at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia.